Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

201.30B

Market cap201.30B

Price-Earnings ratio

10.36

Price-Earnings ratio10.36

Dividend yield

2.78%

Dividend yield2.78%

Average volume

12.16M

Average volume12.16M

High today

$45.23

High today$45.23

Low today

$44.05

Low today$44.05

Open price

$44.17

Open price$44.17

Volume

11.33M

Volume11.33M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 1h

Novo Nordisk Study Highlights Cardiovascular Inflammation Gap And Future Market Potential - simplywall.st

...

The Motley Fool 3h

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly...

TipRanks 7h

Novo Nordisk to showcase new data from its cardiometabolic portfolio at ADA

The company states: “Novo Nordisk (NVO) announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientifi...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

TipRanks 13h

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Nasdaq 2d

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

Key Points The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predic...

Simply Wall St 2d

Oral Wegovy And Cancer Signals Reframe Novo Nordisk GLP 1 Opportunity

EMA committee issues positive opinion on EU marketing authorisation for oral Wegovy (semaglutide) for weight management, including cardiovascular outcomes. Ora...

The Motley Fool 2d

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

The introduction of GLP-1 drugs has revolutionized the way the world looks at weight loss. Taking a shot or a pill to curb one's appetite and lose weight is clo...

Nasdaq 2d

CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has issued a positive opinio...

Simply Wall St 5d

Assessing Novo Nordisk Valuation After Recent Share Price Volatility

Advertisement Recent performance snapshot Novo Nordisk (NYSE:NVO) has drawn attention after a mixed run in the stock, with a gain of about 15% over the past m...

TipRanks 5d

Novo Nordisk Wins CHMP Backing for High-Dose Wegovy Single-Dose Pen in EU

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, person...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.